Cardiotoxicity Mitigation
Cardiotoxicity Mitigation is a therapeutic strategy within the domain of toxicity reduction that specifically targets the prevention, reduction, or management of drug-induced cardiac damage through pharmacological, genetic, or procedural interventions.
474
Publications
21.3K
Citations
3K
Authors
802
Institutions
Publications per year
2017–2026
243
Parents
474
Protective effect of lycopene on adriamycin-induced cardiotoxicity and nephrotoxicity
Seval Yılmaz, Ahmet Ateşşahín, Engin Şahna et al. · Toxicology · 2005 · 267 citations
Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine.
James H. Doroshow, Gershon Y. Locker, Ina Ifrim et al. · Journal of Clinical Investigation · 1981 · 243 citations · Full text
Medicine, Pharmacology, Toxicology +17
1–5 of 474
3K
7
h-index
7
h-index
5
h-index
5
h-index
5
h-index
1–5 of 3K
802

King Saud University
Riyadh, Saudi Arabia
14 h-index
49 publications
2.2K citations
Wuhan University
Wuhan, China
13 h-index
99 publications
5K citations
Renmin Hospital of Wuhan University
Wuhan, China
12 h-index
92 publications
4.8K citations

Chinese Academy of Medical Sciences & Peking Union Medical College
Beijing, China
10 h-index
51 publications
1.6K citations

University of Manitoba
Winnipeg, Canada
10 h-index
58 publications
2.3K citations

Al-Azhar University
Cairo, Egypt
8 h-index
12 publications
653 citations

University of Northern Colorado
Greeley, United States
7 h-index
27 publications
1.9K citations

Zagazig University
Zagazig, Egypt
7 h-index
15 publications
686 citations
1–8 of 802
Repository · 30 publications · 1.5K citations
20
h-index
15 publications · 602 citations
15
h-index
15 publications · 595 citations
14
h-index
13 publications · 415 citations
12
h-index
9 publications · 485 citations
9
h-index
1–5